治疗顽固性高血压和难以控制的高血压的肾脏去神经支配--克罗地亚高血压联盟、克罗地亚高血压学会、克罗地亚心脏学会、克罗地亚血管内倡议、克罗地亚糖尿病和代谢性疾病学会、克罗地亚肾脏协会和克罗地亚医学协会家庭医生学会的共识文件。

IF 2.6 Q2 PERIPHERAL VASCULAR DISEASE Vascular Health and Risk Management Pub Date : 2023-12-11 eCollection Date: 2023-01-01 DOI:10.2147/VHRM.S422773
Bojan Jelaković, Dražen Perkov, Klara Barišić, Nikolina Bukal, Lana Gellineo, Ana Jelaković, Josipa Josipović, Ingrid Prkačin, Tajana Željković Vrkić, Marijana Živko
{"title":"治疗顽固性高血压和难以控制的高血压的肾脏去神经支配--克罗地亚高血压联盟、克罗地亚高血压学会、克罗地亚心脏学会、克罗地亚血管内倡议、克罗地亚糖尿病和代谢性疾病学会、克罗地亚肾脏协会和克罗地亚医学协会家庭医生学会的共识文件。","authors":"Bojan Jelaković, Dražen Perkov, Klara Barišić, Nikolina Bukal, Lana Gellineo, Ana Jelaković, Josipa Josipović, Ingrid Prkačin, Tajana Željković Vrkić, Marijana Živko","doi":"10.2147/VHRM.S422773","DOIUrl":null,"url":null,"abstract":"<p><p>Renal denervation (RDN) as a method of treating arterial hypertension (AH) was introduced in Croatia in 2012. A multidisciplinary team and a network of hospitals that diagnose and treat patients with severe forms of AH were established, and a very strict diagnostic-treatment algorithm was prepared. At monthly meetings patients with truly resistant hypertension who were candidates for RDN were discussed. According to the 2021 ESH position statement and 2023 ESH guidelines, RDN is considered an alternative and additional, not a competitive method of treating patients with various forms of AH which must be performed by following a structured procedure and the patient's preference should be considered. In view of the changes in the global scientific community, the Croatian Hypertension League brings this consensus document on RDN conducted with radiofrequency-based catheter, the only currently available method in Croatia. In this document, exclusion and inclusion criteria are shown, as well as three groups of patients in whom RDN could be considered. The new diagnostic-treatment algorithm is prepared and follow-up procedure is explained. In Croatia, RDN is reimbursed by the national insurance company, thus pharmacoeconomic analyses is also shown. Criteria required by an individual centre to be approved of RDN are listed, and plans for prospective research on RDN in Croatia, including the Croatian registry for RDN, are discussed.</p>","PeriodicalId":23597,"journal":{"name":"Vascular Health and Risk Management","volume":"19 ","pages":"805-826"},"PeriodicalIF":2.6000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724019/pdf/","citationCount":"0","resultStr":"{\"title\":\"Renal Denervation in the Treatment of Resistant Hypertension and Difficult-to-Control Hypertension - Consensus Document of the Croatian Hypertension League - Croatian Society of Hypertension, Croatian Cardiac Society, Croatian Endovascular Initiative, Croatian Society for Diabetes and Metabolic Diseases, Croatian Renal Association, and Croatian Society of Family Physicians of the Croatian Medical Association.\",\"authors\":\"Bojan Jelaković, Dražen Perkov, Klara Barišić, Nikolina Bukal, Lana Gellineo, Ana Jelaković, Josipa Josipović, Ingrid Prkačin, Tajana Željković Vrkić, Marijana Živko\",\"doi\":\"10.2147/VHRM.S422773\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Renal denervation (RDN) as a method of treating arterial hypertension (AH) was introduced in Croatia in 2012. A multidisciplinary team and a network of hospitals that diagnose and treat patients with severe forms of AH were established, and a very strict diagnostic-treatment algorithm was prepared. At monthly meetings patients with truly resistant hypertension who were candidates for RDN were discussed. According to the 2021 ESH position statement and 2023 ESH guidelines, RDN is considered an alternative and additional, not a competitive method of treating patients with various forms of AH which must be performed by following a structured procedure and the patient's preference should be considered. In view of the changes in the global scientific community, the Croatian Hypertension League brings this consensus document on RDN conducted with radiofrequency-based catheter, the only currently available method in Croatia. In this document, exclusion and inclusion criteria are shown, as well as three groups of patients in whom RDN could be considered. The new diagnostic-treatment algorithm is prepared and follow-up procedure is explained. In Croatia, RDN is reimbursed by the national insurance company, thus pharmacoeconomic analyses is also shown. Criteria required by an individual centre to be approved of RDN are listed, and plans for prospective research on RDN in Croatia, including the Croatian registry for RDN, are discussed.</p>\",\"PeriodicalId\":23597,\"journal\":{\"name\":\"Vascular Health and Risk Management\",\"volume\":\"19 \",\"pages\":\"805-826\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724019/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular Health and Risk Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/VHRM.S422773\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Health and Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/VHRM.S422773","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

克罗地亚于 2012 年引入了肾脏去神经支配(RDN)作为治疗动脉高血压(AH)的方法。克罗地亚成立了一个多学科团队和一个医院网络,负责诊断和治疗严重形式的动脉高血压患者,并制定了一套非常严格的诊断-治疗算法。在每月一次的会议上,讨论了作为 RDN 候选者的真正抵抗性高血压患者。根据 2021 年 ESH 立场声明和 2023 年 ESH 指南,RDN 被视为治疗各种形式 AH 患者的替代和补充方法,而非竞争性方法,必须按照结构化的程序进行,并应考虑患者的偏好。鉴于全球科学界的变化,克罗地亚高血压联盟提交了这份关于使用射频导管进行 RDN 的共识文件,这是克罗地亚目前唯一可用的方法。本文件列出了排除和纳入标准,以及可考虑使用 RDN 的三类患者。本文还介绍了新的诊断-治疗算法和随访程序。在克罗地亚,RDN 由国家保险公司报销,因此也显示了药物经济学分析。报告还列出了各中心批准 RDN 所需的标准,并讨论了克罗地亚 RDN 前瞻性研究计划,包括克罗地亚 RDN 登记处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Renal Denervation in the Treatment of Resistant Hypertension and Difficult-to-Control Hypertension - Consensus Document of the Croatian Hypertension League - Croatian Society of Hypertension, Croatian Cardiac Society, Croatian Endovascular Initiative, Croatian Society for Diabetes and Metabolic Diseases, Croatian Renal Association, and Croatian Society of Family Physicians of the Croatian Medical Association.

Renal denervation (RDN) as a method of treating arterial hypertension (AH) was introduced in Croatia in 2012. A multidisciplinary team and a network of hospitals that diagnose and treat patients with severe forms of AH were established, and a very strict diagnostic-treatment algorithm was prepared. At monthly meetings patients with truly resistant hypertension who were candidates for RDN were discussed. According to the 2021 ESH position statement and 2023 ESH guidelines, RDN is considered an alternative and additional, not a competitive method of treating patients with various forms of AH which must be performed by following a structured procedure and the patient's preference should be considered. In view of the changes in the global scientific community, the Croatian Hypertension League brings this consensus document on RDN conducted with radiofrequency-based catheter, the only currently available method in Croatia. In this document, exclusion and inclusion criteria are shown, as well as three groups of patients in whom RDN could be considered. The new diagnostic-treatment algorithm is prepared and follow-up procedure is explained. In Croatia, RDN is reimbursed by the national insurance company, thus pharmacoeconomic analyses is also shown. Criteria required by an individual centre to be approved of RDN are listed, and plans for prospective research on RDN in Croatia, including the Croatian registry for RDN, are discussed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vascular Health and Risk Management
Vascular Health and Risk Management PERIPHERAL VASCULAR DISEASE-
CiteScore
4.20
自引率
3.40%
发文量
109
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention, and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. In addition, the journal will also seek to define drug usage in terms of ultimate uptake and acceptance by the patient and healthcare professional.
期刊最新文献
Characteristic of 24-Hour Blood Pressure Dipping Patterns in Hypertensive Stroke Patients. Assessment of Coronary Artery Disease in Non-Valvular Atrial Fibrillation: Is This Light at the End of the Tunnel? Misdiagnosis of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus in Primary Care: A Report of Two Cases and Literature Review. Clinical Accuracy of the G.LAB MD41A0 Upper Arm Blood Pressure Monitor in Pregnancy and Pre-Eclampsia Using the AAMI/ESH/ISO as Reference Standard. Fatal Acute Limb Ischemia Due to Catastrophic Late Endograft Infection and Adjacent Arterial Infection After Endovascular Aneurysm Repair - A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1